AbbVie (Allergan)

New Capabilities

Co-manufacturer of venetoclax (Venclexta); submitted the supplemental new drug application

For decades, patients diagnosed with chronic lymphocytic leukemia—the most common adult leukemia in Western countries, affecting roughly 23,000 Americans each year—faced a difficult choice: endure rounds of intravenous chemotherapy with harsh side effects, or take targeted pills indefinitely, sometimes for life. On February 20, 2026, the Food and Drug Administration (FDA) approved a combination of two oral drugs, venetoclax and acalabrutinib, that eliminates both burdens. Patients take pills for roughly one year, then stop. In a trial of 867 patients, 77% remained cancer-free at three years.

Updated Feb 20

New Capabilities

Marketing first-approved presbyopia drop Vuity

For 240 years, the solution to presbyopia—the gradual loss of near-vision that affects nearly everyone over 45—has been essentially the same: put lenses in front of your eyes. Benjamin Franklin invented bifocals in 1785. Today, two billion people worldwide rely on reading glasses. On January 29, 2026, the Food and Drug Administration approved YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution), the first dual-agent eye drop for treating this universal condition, marking a pivotal moment in pharmacological presbyopia treatment.

Updated Jan 30